The real impact of mechanical bridge strategy in patients with severe acute infarction.
Results obtained in the past 3 years in patients referred with acute myocardial infarction (AMI) and cardiogenic shock for a mechanical bridge to urgent transplantation permit one to assess the real impact of the present strategy in clinical practice. Ten patients (mean age = 49) were admitted in serious condition (CI = 1.8 +/- 0.2 L/min/m2, PCWP = 28 +/- 6 mmHg, systolic aortic pressure = 88 +/- 20 mmHg, urine output 11 +/- 20 ml/hr) and were treated by maximal sympathomimetic support and i.v. enoximone. Two had to be implanted with a total artificial heart (TAH) and one with a left ventricular assist device (LVAD) for recurrent fibrillation despite hemodynamic improvement, within 8 hr. Two have received transplants and are living well after 20 months. Seven who initially improved markedly have been listed as urgent transplant candidates: two of these have been successfully transplanted, and three died suddenly after 6, 25, and 45 days, respectively. One has undergone successful coronary surgery. One patient (age 62, diabetic) was secondarily rejected for a transplant and died. This experience clearly shows that despite initial spectacular hemodynamic improvement, which was due to optimized medical management, death rate before transplant because of sudden ventricular fibrillation remains unacceptably high. This should prompt early mechanical support, with less invasive systems, in patients with AMI.
Loisance
D
D
Department of Cardiology and Cardiac Surgery, C.H.U. Henri Mondor, Créteil, France.
Deleuze
P
P
Hillion
M L
ML
Dubois-Rande
J L
JL
Saal
J P
JP
Benvenuti
C
C
Shiiya
N
N
Wan
F
F
D000328:Adult; D002316:Cardiotonic Agents; D003131:Combined Modality Therapy; D017335:Enoximone; D005500:Follow-Up Studies; D016027:Heart Transplantation / Q000379:methods; D006354:Heart, Artificial; D006353:Heart-Assist Devices; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000401:mortality / Q000628:therapy*; D011446:Prospective Studies; D012770:Shock, Cardiogenic / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate
D002316:Cardiotonic Agents; D007093:Imidazoles; D017335:Enoximone